{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=66",
    "query": {
      "condition": "Lymphoid",
      "page": 66
    },
    "page_size": 10
  },
  "pagination": {
    "page": 66,
    "page_size": 10,
    "total_count": 3083,
    "total_pages": 309,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=67&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=65&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T00:00:17.715Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04191187",
      "title": "Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Biphenotypic Acute Leukemia",
        "Undifferentiated Leukemia",
        "Prolymphocytic Leukemia",
        "Myelodysplastic Syndromes",
        "Chronic Myelogenous Leukemia",
        "Myeloproliferative Neoplasm",
        "Relapsed Large Cell Lymphoma",
        "Mantle Cell Lymphoma",
        "Hodgkin Lymphoma",
        "Burkitt Lymphoma",
        "Relapsed T-Cell Lymphoma",
        "Relapsed Chronic Lymphocytic Leukemia",
        "Relapsed Small Lymphocytic Lymphoma",
        "Relapsed Marginal B-cell Lymphoma",
        "Relapsed Follicular Lymphoma",
        "Lymphoplasmacytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2019-12-06",
      "completion_date": "2024-02-14",
      "has_results": true,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-11-13T00:00:17.715Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04191187"
    },
    {
      "nct_id": "NCT03011372",
      "title": "A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MPN (Myeloproliferative Neoplasms)"
      ],
      "interventions": [
        {
          "name": "Pemigatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2017-04-25",
      "completion_date": "2024-10-30",
      "has_results": true,
      "last_update_posted_date": "2025-11-18",
      "last_synced_at": "2026-11-13T00:00:17.715Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Duarte, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03011372"
    },
    {
      "nct_id": "NCT02228772",
      "title": "Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Lymphoblastic Lymphoma",
        "B-cell Adult Acute Lymphoblastic Leukemia",
        "T-cell Adult Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "MLN 9708",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "51 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "51 Years to 75 Years"
      },
      "enrollment_count": 19,
      "start_date": "2014-12",
      "completion_date": "2019-11",
      "has_results": false,
      "last_update_posted_date": "2019-11-26",
      "last_synced_at": "2026-11-13T00:00:17.715Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02228772"
    },
    {
      "nct_id": "NCT04189445",
      "title": "Futibatinib in Patients With Specific FGFR Aberrations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumor",
        "Advanced or Metastatic Gastric or Gastroesophageal Cancer",
        "Myeloid or Lymphoid Neoplasms (MLN)"
      ],
      "interventions": [
        {
          "name": "Futibatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taiho Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2020-08-05",
      "completion_date": "2024-11-11",
      "has_results": true,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-11-13T00:00:17.715Z",
      "location_count": 11,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04189445"
    },
    {
      "nct_id": "NCT01351545",
      "title": "A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hematologic Malignancies",
        "Inherited Disorders of Metabolism",
        "Inherited Abnormalities of Platelets",
        "Histiocytic Disorders",
        "Acute Myelogenous Leukemia (AML or ANLL)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Other Acute Leukemia",
        "Chronic Myelogenous Leukemia (CML)",
        "Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases",
        "Other Leukemia",
        "Hodgkin Lymphoma",
        "Non-hodgkin Lymphoma",
        "Multiple Myeloma/ Plasma Cell Disorder (PCD)",
        "Inherited Abnormalities of Erythrocyte Differentiation or Function",
        "Disorders of the Immune System",
        "Autoimmune Diseases",
        "Severe Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Center for International Blood and Marrow Transplant Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 99999,
      "start_date": "2011-10",
      "completion_date": "2041-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-11-13T00:00:17.715Z",
      "location_count": 142,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01351545"
    },
    {
      "nct_id": "NCT00002657",
      "title": "SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "bleomycin sulfate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "1995-05",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2013-01-24",
      "last_synced_at": "2026-11-13T00:00:17.715Z",
      "location_count": 86,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002657"
    },
    {
      "nct_id": "NCT05983965",
      "title": "Study of Tazemetostat in Lymphoid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2024-09-05",
      "completion_date": "2026-03-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-11-13T00:00:17.715Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05983965"
    },
    {
      "nct_id": "NCT00012207",
      "title": "Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2000-09",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2010-08-24",
      "last_synced_at": "2026-11-13T00:00:17.715Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Seattle, Washington",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00012207"
    },
    {
      "nct_id": "NCT00774345",
      "title": "A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "B-cell Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 317,
      "start_date": "2009-01-27",
      "completion_date": "2020-10-27",
      "has_results": true,
      "last_update_posted_date": "2021-12-02",
      "last_synced_at": "2026-11-13T00:00:17.715Z",
      "location_count": 56,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • San Diego, California + 48 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00774345"
    },
    {
      "nct_id": "NCT04827745",
      "title": "Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mixed Phenotype Acute Leukemia (MPAL)",
        "Measurable Residual Disease (MRD)"
      ],
      "interventions": [
        {
          "name": "BLINCYTO (Blinatumomab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2021-06-11",
      "completion_date": "2025-05-22",
      "has_results": false,
      "last_update_posted_date": "2025-07-03",
      "last_synced_at": "2026-11-13T00:00:17.715Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04827745"
    }
  ]
}